Life sciences venture capitalist Vesalius Biocapital has raised 120 million euros in funding, focusing on investment in digital health as well as biotechs.
This week’s news has been dominated by the downfall of ‘rock star’ investment manager Neil Woodford, who has made his name by championing many businesses in UK biotech.
Drug development can be quite a risky business at the best of times, but particularly in the biotech sector where companies may only have a few assets to their name.